Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III

NCT06971094 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

SMA - Spinal Muscular Atrophy

Interventions

GENETIC: GC101 adeno-associated virus injection

Sponsor

GeneCradle Inc